Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Arvinas, Inc.
  6. Summary
    ARVN   US04335A1051

ARVINAS, INC.

(ARVN)
  Report
Delayed Quote. Delayed Nasdaq - 09/24 04:00:00 pm
88.61 USD   -5.92%
09/13ARVINAS : Purchase Agreement (Form 8-K)
PU
09/13ARVINAS, INC. : Other Events (form 8-K)
AQ
09/09ARVINAS : BofA Securities Starts Arvinas at Buy with $110 Price Target
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
92.29(c) 93.01(c) 93.69(c) 94.19(c) 88.61 Last
207 171 151 911 357 374 352 578 309 973 Volume
-4.34% +0.78% +0.73% +0.53% -5.92% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 68,2 M - -
Net income 2021 45,0 M - -
Net cash position 2021 1 540 M - -
P/E ratio 2021 91,5x
Yield 2021 -
Sales 2022 90,3 M - -
Net income 2022 -145 M - -
Net cash position 2022 1 224 M - -
P/E ratio 2022 -30,9x
Yield 2022 -
Capitalization 4 666 M 4 666 M -
EV / Sales 2021 45,8x
EV / Sales 2022 38,1x
Nbr of Employees 179
Free-Float 82,0%
More Financials
Company
Arvinas, Inc., formerly Arvinas Holding Co LLC, is a development staged biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to degrade disease-causing proteins. The Company uses its technology platform to engineer proteolysis targeting chimeras (PROTACs), which are designed to harness the bodyÔÇÖs own natural protein disposal system to selectively and efficiently... 
Sector
Biotechnology & Medical Research
Calendar
09/28 | 09:20amPresentation
More about the company
Ratings of Arvinas, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ARVINAS, INC.
09/13ARVINAS : Purchase Agreement (Form 8-K)
PU
09/13ARVINAS, INC. : Other Events (form 8-K)
AQ
09/09ARVINAS : BofA Securities Starts Arvinas at Buy with $110 Price Target
MT
09/01ARVINAS : to Participate in Upcoming Virtual Investor Conferences
AQ
08/09ARVINAS : Roth Capital Adjusts Price Target on Arvinas to $135 From $120, Maintains Buy Ra..
MT
08/09ARVINAS : Insilico Medicine Reaches R&D Collaboration Pact With Arvinas
MT
08/09Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas
CI
08/09ARVINAS : Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas
AQ
08/06ARVINAS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statem..
AQ
08/05ARVINAS : Management's Discussion and Analysis of Financial Condition and Results of Opera..
AQ
08/05ARVINAS, INC. : Results of Operations and Financial Condition, Financial Statements and Ex..
AQ
08/05ARVINAS : Wedbush Adjusts Price Target for Arvinas to $115 From $113, Maintains Outperform..
MT
08/05ARVINAS : Earnings Flash (ARVN) ARVINAS Posts Q2 Revenue $5.5M
MT
08/05ARVINAS : Earnings Flash (ARVN) ARVINAS Posts Q2 Loss $-1.03
MT
08/05ARVINAS : Reports Second Quarter 2021 Financial Results and Provides Corporate Update
AQ
More news
News in other languages on ARVINAS, INC.
07/23DGAP-NEWS : Biotechbranche mit solidem 2. Quartal -2-
07/22PFIZER : collaboration avec Arvinas dans le cancer du sein
04/23DGAP-NEWS : BB BIOTECH AG: Erfolgreiche -2-
01/22BB Biotech a étoffé ses gains en 2020 et va en faire profiter ses actionnaires
2020BB Biotech im zweiten Quartal mit Milliardengewinn dank Biotech-Hype
More news
Analyst Recommendations on ARVINAS, INC.
More recommendations
Chart ARVINAS, INC.
Duration : Period :
Arvinas, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARVINAS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 94,19 $
Average target price 130,77 $
Spread / Average Target 38,8%
EPS Revisions
Managers and Directors
John G. Houston President, Chief Executive Officer & Director
Sean A. Cassidy Chief Financial Officer
Timothy M. Shannon Chairman
Ian Taylor Chief Scientific Officer
Kimberly Wehger Vice President-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ARVINAS, INC.4.33%4 959
GILEAD SCIENCES, INC.22.19%89 886
BIONTECH SE309.08%85 255
WUXI APPTEC CO., LTD.34.39%68 592
REGENERON PHARMACEUTICALS32.25%67 216
VERTEX PHARMACEUTICALS-22.31%48 018